LEO 43204

DRUG4 trials

Sponsors

LEO Pharma

Conditions

Actinic Keratosis

Phase 1

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

CompletedNCT02100813

LEO PharmaActinic Keratosis

Start: 2014-05-31End: 2015-03-31Updated: 2025-03-06

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

CompletedNCT02120456

LEO PharmaActinic Keratosis

Start: 2014-05-31End: 2015-05-31Updated: 2025-03-06

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

CompletedNCT02650505

LEO PharmaActinic Keratosis

Start: 2016-02-29End: 2016-06-30Updated: 2025-02-24

Phase 2

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

CompletedNCT02305888

LEO PharmaActinic Keratosis

Start: 2015-03-31End: 2015-08-31Updated: 2025-03-10